ABOS
Acumen Pharmaceuticals, Inc. NASDAQ Listed Jul 1, 2021$2.47
Mkt Cap $149.6M
52w Low $0.96
57.2% of range
52w High $3.60
50d MA $2.78
200d MA $2.09
P/E (TTM)
-1.2x
EV/EBITDA
-0.8x
P/B
2.0x
Debt/Equity
0.4x
ROE
-172.3%
P/FCF
-1.1x
RSI (14)
—
ATR (14)
—
Beta
0.34
50d MA
$2.78
200d MA
$2.09
Avg Volume
570.2K
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
CIK (SEC)
Phone
434 297 1000
427 Park Street · Newton, VA 22902 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.50 | -0.41 | +18.0% | 2.55 | -2.7% | -11.4% | -14.1% | -7.5% | +0.0% | +5.9% | — |
| Nov 12, 2025 | AMC | -0.63 | -0.44 | +30.2% | 1.95 | -2.6% | -7.2% | -11.3% | -19.0% | -14.9% | -20.5% | — |
| Aug 12, 2025 | AMC | -0.54 | -0.68 | -25.9% | 1.26 | +0.8% | +0.8% | +11.1% | +12.7% | +13.5% | +9.5% | — |
| May 13, 2025 | AMC | -0.56 | -0.48 | +14.3% | 1.05 | +0.0% | -6.7% | -3.8% | +1.9% | +1.9% | +1.0% | — |
| Mar 27, 2025 | AMC | -0.47 | -0.62 | -31.9% | 1.23 | +0.8% | -3.3% | -10.6% | -12.2% | -12.2% | -19.7% | — |
| Nov 12, 2024 | AMC | -0.36 | -0.50 | -38.9% | 2.68 | +1.9% | -5.6% | -2.6% | -10.4% | -16.4% | -10.8% | — |
| Aug 13, 2024 | AMC | -0.28 | -0.34 | -21.4% | 2.77 | +0.4% | -9.0% | -6.9% | -7.2% | +2.2% | +2.2% | — |
| May 14, 2024 | AMC | -0.23 | -0.25 | -8.7% | 3.69 | +0.0% | +3.0% | +1.1% | -1.1% | +4.1% | +3.3% | — |
| Mar 26, 2024 | AMC | -0.29 | -0.29 | +0.0% | 3.75 | +0.0% | +9.3% | +8.0% | +6.9% | +1.1% | +4.3% | — |
| Nov 13, 2023 | AMC | -0.31 | -0.24 | +22.6% | 2.03 | +3.4% | +4.9% | +16.7% | +10.3% | +12.3% | +16.3% | — |
| Aug 8, 2023 | AMC | -0.36 | -0.28 | +22.2% | 7.00 | +0.0% | -3.1% | +0.6% | +2.0% | +3.1% | +1.7% | — |
| May 9, 2023 | AMC | -0.33 | -0.28 | +15.2% | 5.73 | +0.3% | +15.0% | +0.0% | -2.3% | +8.2% | -2.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | BTIG | Maintains | Buy → Buy | — | $2.63 | $2.56 | -2.7% | -3.0% | -14.1% | -16.7% | -10.3% | -3.0% |
| Mar 16 | BTIG | Maintains | Buy → Buy | — | $3.27 | $3.50 | +7.0% | +2.1% | -5.5% | -10.7% | -10.7% | -18.3% |
| Jan 27 | BTIG | Maintains | Buy → Buy | — | $2.08 | $2.24 | +7.7% | +30.8% | +35.1% | +34.1% | +25.0% | +24.5% |
| Nov 18 | BofA Securities | Maintains | Buy → Buy | — | $1.58 | $1.60 | +1.3% | +5.1% | -1.9% | -1.3% | -0.6% | +7.6% |
| Aug 25 | BofA Securities | Maintains | Buy → Buy | — | $1.53 | $1.52 | -0.7% | -1.3% | -4.6% | -9.2% | -14.4% | -11.1% |
| Mar 28 | UBS | Maintains | Buy → Buy | — | $1.23 | $1.24 | +0.8% | -3.3% | -10.6% | -12.2% | -12.2% | -19.7% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.23 | $1.24 | +0.8% | -3.3% | -10.6% | -12.2% | -12.2% | -19.7% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.68 | $2.73 | +1.9% | -5.6% | -2.6% | -10.4% | -16.4% | -10.8% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.50 | $2.50 | +0.0% | -4.4% | -5.2% | -4.8% | -5.6% | -8.4% |
| Aug 15 | UBS | Maintains | Buy → Buy | — | $2.52 | $2.61 | +3.6% | +2.4% | +2.0% | +12.3% | +12.3% | +13.1% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.77 | $2.78 | +0.4% | -9.0% | -6.9% | -7.2% | +2.2% | +2.2% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.69 | $3.69 | +0.0% | +3.0% | +1.1% | -1.1% | +4.1% | +3.3% |
| Mar 31 | UBS | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.75 | $3.75 | +0.0% | +9.3% | +8.0% | +6.9% | +1.1% | +4.3% |
| Aug 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $7.00 | $7.00 | +0.0% | -3.1% | +0.6% | +2.0% | +3.1% | +1.7% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.00 | $7.00 | +0.0% | -3.1% | +0.6% | +2.0% | +3.1% | +1.7% |
| Jul 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.28 | $11.01 | +75.3% | +54.8% | +27.4% | +18.0% | +16.4% | +17.8% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.28 | $11.01 | +75.3% | +54.8% | +27.4% | +18.0% | +16.4% | +17.8% |
| May 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.45 | $5.69 | +4.4% | +2.6% | +9.4% | -2.6% | -4.6% | -3.7% |
| Mar 28 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.21 | $4.25 | +1.0% | -4.8% | -3.3% | -3.1% | -3.6% | +2.4% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.21 | $4.25 | +1.0% | -4.8% | -3.3% | -3.1% | -3.6% | +2.4% |
| Feb 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.65 | $6.50 | -2.3% | -10.7% | -13.5% | -10.1% | -11.9% | -10.5% |
| Nov 15 | Credit Suisse | Maintains | Outperform → Outperform | — | $6.14 | $6.17 | +0.5% | +5.0% | +0.2% | +6.0% | -1.0% | +3.4% |
| Oct 5 | BTIG | Maintains | Buy → Buy | — | $9.55 | $10.32 | +8.1% | +6.5% | +5.4% | +2.8% | -1.0% | -5.8% |
| Jul 15 | BTIG | Maintains | Buy → Buy | — | $6.26 | $6.47 | +3.4% | +0.5% | -6.2% | -3.2% | -7.0% | -1.6% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $4.92 | +0.8% | -3.7% | -3.5% | -2.7% | +12.7% | +23.0% |
| Mar 29 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.66 | $4.75 | +1.9% | -6.0% | -14.8% | -16.1% | -13.9% | -12.2% |
| Jan 21 | BofA Securities | Upgrade | Neutral → Buy | — | $4.99 | $5.20 | +4.2% | +3.8% | +4.8% | +2.0% | -0.2% | -2.8% |
| Jul 26 | BofA Securities | Maintains | Neutral → Neutral | — | $17.08 | $17.17 | +0.5% | -3.0% | -15.1% | -12.8% | -10.3% | -9.4% |
| Jul 26 | Stifel | Maintains | Buy → Buy | — | $17.08 | $17.17 | +0.5% | -3.0% | -15.1% | -12.8% | -10.3% | -9.4% |
| Jul 26 | UBS | Maintains | Buy → Buy | — | $17.08 | $17.17 | +0.5% | -3.0% | -15.1% | -12.8% | -10.3% | -9.4% |
| Jul 26 | Credit Suisse | Maintains | Outperform → Outperform | — | $17.08 | $17.17 | +0.5% | -3.0% | -15.1% | -12.8% | -10.3% | -9.4% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ABOS disclosed material non-public information under Reg FD, suggesting a significant business development or event occurred that investors need to evaluate for stock impact.
Mar 26
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
ABOS announced an equity issuance, which will dilute existing shareholders' ownership percentages and could pressure the stock price unless proceeds fund significant growth initiatives.
Mar 16
Data updated apr 24, 2026 10:16am
· Source: massive.com